Rollprint adds director of technical services

New position created to add r&d capacity and support customers

Rollprint Packaging Products, the US supplier of packaging materials for the healthcare and food industries, has welcomed Dr Henk Blom as director of technical services. He reports to Doug Dodrill, vice president of technology.

‘As the demand for Rollprint products continues to grow, it was important to support our customers with additional r&d capability so we created the new position,’ Dodrill said.

Having spent the past 12 years at Baxter Healthcare Corporation, Blom brings significant medical device technical expertise to the position.

‘Henk’s background enables him to look at the big picture – materials, distribution, processing, failure analysis, etc. – to help our customers find ideal packaging solutions for their specific product requirements,’ added Dodrill.

You may also like

Packaging

Easy-to-open Barex replacement takes on single-dose applications

Peelable Exponent is designed for hard-to-hold and sensitive chemicals
Packaging

Rollprint introduces Exponent clear flexible film for high-barrier pharmaceutical applications

The result of a collaboration between Rollprint and Ineos
Packaging

Rollprint Ghost technology thwarts counterfeiters

The process creates a repeating watermark embedded in flexible packaging materials
Packaging

Colour-changing sealant enhances pack security

Allows a film of one colour to transfer a peel indicator of a different colour
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development

AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment

AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy
Subscribe now